canakinumab
Novartis
['trigger', 'lung', 'card', 'canakinumab']
canakinumab, an interleukin (il) 1 inhibitory antibody, was studied in cantos to reduce incidence of heart attacks, stroke or cardiovascular death. actually it found less lung cancer, triggering a whole suite of lung cancer studies, one of these presented at #esmo2022 today 1/2 
Associate Professor and Medical Oncologist at University of Ottawa, Past President of Lung Cancer Canada, and a cricket fan!